James S Blachly

58PUBLICATIONS
267CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)HaematologyMolecular targetsMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (58)

|May 08, 2026
Biallelic germline MBD4 mutations predispose to colorectal polyposis, hypermutated AML, and schwannomas.

|Apr 22, 2026
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.

|Apr 14, 2026
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Clive S Zent, Enrico Tiacci, Robert J Kreitman

|Apr 06, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Naval Daver, James S Blachly, Armin Ghobadi

|Nov 05, 2025
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia.

Britten K Gordon, Elizabeth M Muhowski, Jyotsana Singh

|Sep 19, 2025
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).

Monica Cusan, Karilyn Larkin, Deedra Nicolet

Pageof 10

Frequent Collaborators

12 joint publications

Shelley Orwick

11 joint publications

Alice S Mims

9 joint publications

Krzysztof Mrózek

6 joint publications

Rosa Lapalombella